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One-sentence summary: To elucidate patterns in post-translational protein 
modifications that may point to characteristic disease signatures and etiology in lung 
cancer, an integrated analysis of protein phosphorylation, acetylation and methylation in 
lung cancer cell lines is combined with protein-protein interactions to outline and extend 
cell signaling pathways.  
Abstract 
Protein post-translational modifications (PTMs) have typically been studied 
independently, yet many proteins are modified by more than one PTM type, and how 
cell signaling pathways integrate this information is largely unknown. We coupled 
immunoprecipitation using PTM-specific antibodies with Tandem Mass Tag (TMT) mass 
spectrometry to simultaneously examine phosphorylation, methylation, and acetylation 
in 45 lung cancer cell lines compared to normal lung tissue, and cell lines treated with 
anti-cancer drugs. This represents the first large-scale integrative analysis of these 
PTMs together. A cluster-filtered network (CFN) approach was used to interrogate the 
data. Cell signaling pathways were outlined by clustering patterns in PTMs. We 
employed the t-distributed stochastic neighbor embedding (t-SNE) method to identify 
PTM clusters. PTM clusters were then integrated with known protein-protein interactions 
(PPI) to elucidate functional cell signaling pathways. The CFN identifies known and new 
cell signaling pathways specific to lung cancer cell lines. We found that a number of 
proteins modified by more than one type of PTM had inverse relationships between 
different PTMs, suggesting that molecular exclusive “OR” gates govern a surprisingly 
large number of signal transduction events. We also show that the acetyltransferase 
EP300 appears to be a hub in the network of pathways involving different PTMs. In 
addition, the data shed light on the mechanism of action of geldanamycin, a HSP90 
inhibitor. Cell signaling pathways employing acetylation, methylation, and 
phosphorylation are revealed to regulate the cytoskeleton, membrane traffic, and control 
of gene expression through RNA binding proteins.   
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Introduction
Proteins covalently attach moieties such as phosphate, methyl and acetyl groups to 
other proteins to regulate cell signaling events crucial for all cellular physiological 
functions including differentiation, proliferation, cell movement, and cell death. In many 
human diseases, these cell signaling mechanisms go awry (1). Much progress has 
been made in identifying proteins that attach (writers), recognize (readers), and remove 
(erasers) different post-translational modifications (PTMs) (2), while understanding of 
these mechanisms has led to the development of targeted therapeutics, for example, 
cancer treatments that target kinases (3), histone deacetylases (4), and bromodomains, 
which are the associated structures of readers of acetylation (5, 6). 
 
The canonical view of PTMs is that protein acetylation and methylation are mainly 
involved in epigenetic chromatin modifications, while signal transduction pathways are 
mainly regulated via phosphorylation. This view dominated the field mainly because 
different modification types have been typically studied independently. However, there is 
now increasing appreciation that histones are not the only class of proteins affected by 
acetylation and methylation (4, 7). This means that drugs targeting enzymes 
responsible for regulating methylation and acetylation of histones may have a much 
broader effect. It is therefore important to understand in detail molecular signaling 
pathways that involve these PTMs. In addition, further understanding of cell signaling 
pathways will provide new opportunities for therapeutic intervention. For example, 
multiple PTMs are involved in signaling cascades that are linked to neurological 
disorders (8), and the innate immune response (9).
 
Here we sought to understand molecular signaling pathways that are active in lung 
tumor-derived cell lines by simultaneously examining patterns of protein 
phosphorylation, methylation, and acetylation on a large scale. The data we collected 
provide a unique opportunity for an integrated study of cell signaling networks involving 
these three different PTMs. Our goal is to define the relationship between kinases, 
phosphatases, acetyltransferases, deacetylases, methyltransferases, and 
demethylases. Our approach was to integrate two different kinds of information: 
clustering based on statistical relationships among various types of PTMs, and protein-
protein interactions data from public databases (10). 
The sequencing of the human genome provided a parts list of many of the molecular 
constituents that make up the human cell, but we still have a limited understanding 
about how these parts interact and are organized into functional complexes to regulate 
the cell signaling pathways that govern molecular biological processes. Protein-protein 
interaction (PPI) databases attempt to catalog how proteins interact with one another, 
and how these interactions are organized into networks (11-16). Networks are useful to 
model signal transduction pathways (17-22), but these models are difficult to 
understand and validate because such models are complex, they integrate information 
from a variety of sources, and commonly are not specific to a particular tissue or cell 
type in the proper context. They also suffer from biases such as literature focus biases 
or experimental platform biases. Here, we hypothesize that empirical information about 
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PTMs may be used as evidence that can constrain the complexity of cell signaling 
models to better understand the system under study (10, 23). We reason that clustering 
of PTMs under different conditions reveals patterns specific to the system, in this case, 
lung cancer cell lines. Clusters identified by statistical relationships that contain proteins 
known to interact likely represent functional cell signaling pathways. This data-driven 
modeling approach (24) is somewhat analogous to using gene co-expression data to 
identify cell signaling pathways in yeast (25). However, PTMs are much closer to cell 
signaling events than mRNA co-expression, which makes our approach more likely to 
identify cell signaling events upstream of gene expression changes (10).
We used immunoprecipitation with antibodies specific for tyrosine and serine/threonine 
phosphorylation, lysine acetylation, and lysine and arginine methylation, coupled with 
mass spectrometry. This technique was originally described to study only 
phosphorylated proteins (10, 26-28). Mass spectrometry determines the identity of 
peptides with modified residues, and the relative amounts of these peptides. This 
method has a low false positive rate, but a high false negative rate. This is mainly due to 
stochastic sampling of peptides for detection and subsequent fragmentation (29-33). 
This limitation of mass spectrometry introduces two challenges: 1) the resulting data 
has a large number of missing values; and 2) comparing experimental conditions is 
difficult when peptides are stochastically detected. Tandem Mass Tag (TMT) 
experiments surmount the latter issue by labelling samples with different isotopic mass 
tags, and mixing them, so that when a peptide is selected by the mass spectrometer, 
different tags are resolved upon subsequent fragmentation (34). This allows direct 
comparison of peptide amounts in multiplexed samples and accurate calculation of 
treatment-to-control ratios within a TMT multiplex. When comparing two or more TMT 
runs, however, there are still a large fraction of missing values because of the stochastic 
nature of detection. Therefore, the TMT data are different from gene expression data 
derived from microarray or RNA-seq experiments, and thus require special 
considerations for data analysis (see Supplementary Information). Building on previous 
work (10, 23), we evaluated different methods for handling these data, which can be 
grouped into three approaches: imputing missing values, pairwise-complete, and 
penalized matrix decomposition. Statistical relationships (Spearman correlation; 
Euclidean distance) were embedded into a reduced dimension representation using t-
distributed stochastic neighbor embedding (t-SNE), which is effective in identifying 
clusters in a wide variety of non-linear real-world and biological data (10, 23, 35-38). 
Penalized matrix decomposition followed by an additional t-SNE step further resolved 
large clusters to produce a co-clustered correlation network (CCCN) for strongly 
associated modifications. This clustering method was used to decipher cell signaling 
pathways by filtering PPI edges to retain only interactions between proteins whose 
modifications co-clustered, creating a cluster-filtered network (CFN). The CFN and 
CCCN data structures were further evaluated in a number of ways, and then used to 
outline cell signaling pathways, starting from the target proteins that are affected by 
drugs. The analysis highlights molecular pathways defined by highly correlated clusters 
of PTMs, and reveals antagonistic relationships among PTMs that are negatively 
correlated. Signaling pathways that employ multiple PTMs involve heat shock, RNA 
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Our goal is to use large scale mass spectrometry data to integrate cell signaling 
pathways that involve protein phosphorylation, methylation, and acetylation. We 
hypothesize that proteins that interact with one another and are post-translationally 
modified in patterns identified by close statistical relationships likely represent functional 
cell signaling pathways. We therefore combined PTM clustering information with PPI 
databases to create the CFN. The CFN only retains PPIs whose modifications co-
cluster (Figure 1A). The resulting network only retains interactions between proteins that 
are also supported by protein modification data (10).
 
PTM data were obtained using immunoprecipitation with antibodies that are non-specific 
to individual proteins but specific to PTMs and combined with Tandem Mass Tag (TMT) 
mass spectrometry (Figure 1B). 45 lung cancer cell lines were compared to normal lung 
tissue in nine multiplex runs. In addition, selected lung cancer cell lines were treated 
with the anti-cancer drugs: crizotinib, gefitinib, gleevec, and geldanamycin in six 
multiplex runs. Since each experiment represents a different state of the lung cancer 
cell line signaling system, and because combining data from different cell lines improves 
the quality of clustering (10), we combined comparison of cell lines to normal lung tissue 
(8729 modifications) and drug treated cell lines (9321 modifications) into one data 
matrix containing 13798 unique modifications; 90 samples from 15 independent 
experiments (6 samples in each experiment). The combined data matrix contained 78% 
missing values because there are a large number of PTMs that were not detected 
across different multiplex runs. Missing values may represent either the absence of 
PTMs in samples or simply the lack of data, so we developed approaches to reduce 
their influence on data analysis (10, 23).
Since identification of groups of statistically-related PTMs from this sparse datasets is 
challenging, we evaluated different methods to derive clusters from the statistical 
relationships between the identified PTMs (described in detail in Supplementary 
Information). We found that the t-SNE method when used with dissimilarity 
representations was the most effective at resolving meaningful clusters based on the 
uniformity and density of each cluster, and the number of prior knowledge PPI found 
among the proteins within the identified clusters (Figures S1, S2)(10, 23). In order to 
utilize the PTM data to outline cell signaling pathways (Figure 1A), we evaluated 
analytical methods that identify PTM clusters whose proteins tend to interact (Figures 
S3, S4). We found that breaking up large clusters (>80 PTMs) by applying penalized 
matrix decomposition (PMD), and another round of t-SNE, worked best for defining 
clusters that are most justifiable by several criteria (Figure S4). 
 4
Well-studied proteins have more interactions within PPI databases. Hence, filtering 
edges using PTM clustering enriched for interactions specific to the lung cancer cell line 
data and mitigated the bias in PPI databases towards well-studied proteins (Figures S5, 
S6). There is a weak correlation between CFN betweenness, a measure that indicates 
how frequently proteins are found on shortest paths through the network, and the 
number of PTMs found on each protein (Figure S7). However, the most highly modified 
proteins were not the proteins that were common to many paths, having high 
betweenness. We conclude that the number of modifications does not always correlate 
with serving as a hub within cell signaling pathways, though some highly modified 
proteins may act as hubs. We defined the minimum Spearman correlation to be used to 
delineate edges that represent correlations between PTMs (Figure 1A), by examining 
the effect on network size and density (Figures S8, S9). Finally, using drug responses 
that affect known kinase pathways, we determined that binning large ratio values and 
using log2-transformed data for clustering produced the best results (Figure S10). This 
is likely because TMT ratio data contains extreme values, which may skew correlation 
analyses, and it can be argued that PTM ratios beyond 100-fold are not functionally 
different.
To summarize, we have established an effective method to cluster PTM data derived 
from TMT mass spectrometry, and used these PTM clusters to filter PPI in a CFN that 
outlines cell signaling pathways in lung cancer cell lines (Figure 1A). We have also 
defined a threshold for Spearman correlations between PTMs to display edges in a 
CCCN (Figure 1C). Both of these networks are available for further exploration at 
https://cynetworkbrowser.umt.edu. We next use these networks to examine pathways 
from drug targets to proteins whose PTMs were affected by drug treatment.  
Pathways in cluster-filtered networks based on drug-affected PTMs 
To outline cell signaling pathways active in lung cancer cell lines, we began with drugs 
that directly inhibit receptor tyrosine kinases. We reasoned that RTK inhibitors will affect 
kinase pathways to affect phosphorylation and other PTMs.  We traced pathways by 
identifying shortest paths in the CFN from known RTK drug targets to other proteins 
whose PTMs changed at least two-fold after drug treatment. Crizotinib, which inhibits 
MET and ALK, inhibited modification of a number of proteins that are involved in 
cytoskeletal rearrangements and adhesion (Figure 2A; blue indicates a decrease in 
PTMs), consistent with the oncogenic role MET is playing in metastasis (39). EGFR 
phosphorylation was also decreased by crizotinib (Figure 2A), and the EGFR inhibitor, 
gefitinib decreased MET phosphorylation (Figure 2B), indicating crosstalk between 
these RTKs or possibly off-target effects. The CFN connections downstream of MET, 
ALK, and EGFR link to the tyrosine kinase LYN, the tyrosine phosphatase PTPN11/
SHP2, and the adaptor/scaffold proteins IRS1 and CRK(40). These connections indicate 
known interactions supported by the statistical clustering of PTMs.  
In addition to decreases in phosphorylation of downstream targets, we noted an 
increase in acetylation of many proteins (Figure 2B, yellow nodes). In a group of 
proteins that were both phosphorylated and acetylated, phosphorylation decreased and 
 5
acetylation increased with gefitinib treatment (Figure 2C). The acetyltransferase EP300 
itself showed increased acetylation with gefitinib treatment, and was linked to HSP90 in 
the CFN (Figure 2B). Also present was fatty acid synthase (FASN), whose activity and 
expression is controlled by EP300 (41). EP300 and HSP90 have many links in the CFN 
to proteins dually modified by both phosphorylation and acetylation (Figure 2B). Thus, 
examination of several PTMs in the same experiment reveals an unexpected 
relationship between phosphorylation and acetylation. Filtering PPIs by PTM 
modification clustering highlights links between cytoskeletal proteins, RNA-binding 
proteins, and heat shock proteins in lung cancer cell lines.
HSP90 proteins, together with CDC37, act as chaperones for a large number of 
kinases, including RTKs, and are required for regulation of activity as well as their initial 
folding (42). The mechanisms of action of the HSP90 inhibitor geldanamycin are not 
well-understood compared with the other anti-cancer drugs employed in this study. Heat 
maps showing PTMs affected by more than 2-fold by geldanamycin reveal that, in 
addition to HSPs (Figure 3A), many proteins involved in regulating endocytosis (Figure 
3B) and cytoskeletal dynamics (Figure 3C) were affected by geldanamycin. This is 
consistent with reports that geldanamycin affects endocytic membrane trafficking and 
cytoskeletal dynamics (43-45). Examination of the shortest paths between HSP90, the 
known target of geldanamycin, and proteins whose PTMs were affected by 
geldanamycin included acetyltransferase EP300 interacting with HSP90AA1 (Figure 
3D). As mentioned above, proteins that have high betweenness are likely to be hubs in 
the network, that is, connect many cell signaling pathways (Figure S7). These include 
HSP90AA1 and several other proteins linked to it in the geldanamycin subnetwork 
(Figure 3D), including the 14-3-3 proteins YWHAQ and YWHAZ; the RNA-binding 
protein, NPM1; and the heat shock proteins HSPA8, HSPA1B; and β-actin (ACTB). 
Geldanamycin treatment also affected phosphorylation of the RTKs ALK, AXL, EGFR, 
ERBB3, and IGF1R (Figure 3D; all were decreased except AXL and ERBB3). 
These results suggest that geldanamycin may affect the balance between 
phosphorylation and acetylation by influencing EP300 through interaction with HSP90 
proteins. This in turn affects endocytosis (e.g., DYNC1I2, EPS8, CAV1, and clathrin 
heavy chain, CLTC) as well as microtubules, actin, other cytoskeletal elements (e.g., 
spectrin, SPTAN1; keratins, KRT7, KRT8; Figure 3). Protein methylation may also be 
involved. Changes in methylation were also observed in response to geldanamycin, and 
phosphorylation of the histone lysine methyltransferases WHSC1/NSD2 and NSD1 
were reduced (Figure 3). In fact, there are CFN links between EP300 and kinases, 
phosphatases, another acetyltransferase (CLOCK), methyltransferases (PRMT1, 
ASH1L) and the actin-regulating proteins RAC1 and CDC42 (Figure 4A).  
Specific PTM relationships in the pathways that connect EGFR to EP300 can be 
visualized by showing PTMs and their correlation edges on the CFN graph (Figure 4B). 
In the graphs in Figure 4, node size and color indicate comparison of individual PTMs, 
or the sum of all PTMs for a protein, in cell lines compared to normal lung tissue. The 
same graphs indicating fold change in response to drug treatments are shown in 
Supplemental Figure S11. Individual PTMs on EP300 changed in response to different 
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conditions, and these changes occurred concomitantly with PTMs on other proteins that 
co-cluster with EP300 PTMs (Figure S12). For example, EP300 phospho-S1897 was 
down-regulated in lung cancer cells compared to normal lung tissue along with two 
phosphorylation sites on BCAR3 (Figure S12A, bottom), while EP300 acetylation sites 
K1674 and K1760, along with RAC1 and CDC42 acetylation sites, were increased by 
gefitinib treatment (Figure S12C, top and middle left, respectively). These data indicate 
that EP300 likely plays a central role in cytoplasmic signaling in addition to its previously 
described role as a histone acetyltransferase. The inverse relationship between 
phosphorylation and acetylation on EP300 (Figure S12) and other proteins (Figure 2) 
gives rise to the hypothesis that there is an antagonistic relationship between particular 
sites of acetylation and phosphorylation on cell signaling proteins. These sites may be 
indicators of mutually opposing mechanisms or pathways.
Evidence for antagonistic relationships among PTMs
The hypothesis that there is an antagonistic or dueling relationship between 
phosphorylation and acetylation sites leads to two predictions. First, we should expect 
to find negative correlations between a subset of phosphorylation and acetylation sites 
for proteins modified with both PTMs. The distribution of correlations between 
phosphorylation and acetylation sites on the same protein was significantly different 
than that of dual phosphorylation or acetylation (Figure 5A). We found 269 such 
phosphorylation and acetylation modifications with Spearman correlation lower than –
0.5 in 112 proteins in the lung cancer cell line PTM data (highlighted in blue in Figure 
5A). Both tyrosine phosphorylation and serine/threonine phosphorylation exhibited 
negative correlations with acetylation (Figure S13). Negative correlations can be 
visualized as blue edges on a combined CFN-CCCN as in Figure 5B, which shows 
proteins that are involved with endocytosis and the actin cytoskeleton that are affected 
by geldanamycin. Cortactin (CTTN), for example, has a large number of 
phosphorylation sites negatively correlated with its acetylation sites that are affected in 
opposite ways by geldanamycin (Figure 5B, upper right; 5C). Clathrin is another 
example where phosphorylation and acetylation sites are negatively correlated, though 
not all sites were affected by geldanamycin, or detected in the drug treatment 
experiments. Figure 5D also highlights two cliques of highly correlated co-clustered 
PTMs, identified by yellow edges. EGFR p Y869 clustered with MET pY1003 in one 
clique, while different EGFR phosphorylation sites clustered with proteins involved with 
endocytosis (EPS8, CLTC) in the other clique. 
The second prediction of the hypothesized dueling relationship between certain 
phosphorylation and acetylation sites is that there should be interactions between 
acetyl-binding proteins containing bromo (or BET) domains, which bind to acetylated 
lysine moieties, and kinase signaling pathways (5). Figure 5E shows a network of 
interactions in the CFN among dually phosphorylated and acetylated proteins, kinases 
and bromodomain proteins (highlighted in red). Bromodomain-containing proteins are 
more likely to interact with dually phosphorylated/acetylated proteins than acetylated 
proteins in general, or proteins modified by phosphorylation or methylation (Figure 5F). 
That there are more CFN interactions between bromodomain-containing proteins and 
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those dually phosphorylated and acetylated than all other groups of proteins, combined 
with the fact that gefitinib (Figure 2B, C) and geldanamycin (Figure 3) caused decreases 
in phosphorylation and concomitant increases in acetylation for a large number of 
proteins, strongly support the hypothesis that certain phosphorylation and acetylation 
sites play antagonistic or mutually opposing roles for proteins identified in this study.
The data suggest the hypothesis that the intracellular location of proteins may change 
when their phosphorylation and acetylation rates go in opposite directions. To test this 
hypothesis, we performed cell fractionation experiments that effectively separate 
organelles including endosomes and lysosomes, and membrane compartments 
distinguished by resistance to non-ionic detergents (lipid rafts; Figure 6A) (10, 46, 47). 
Geldanamycin treatment caused changes in the intracellular location of proteins with 
negative correlations between phosphorylation and acetylation, determined by mass 
spectrometry (Figure 6B, C), and western blotting (Figures 6D, E, and S14). Many 
dually modified proteins increased in detergent-resistant lipid raft fractions (rafts2-4), 
including HSPs and chaperones (HSP90AA1, HSPA4, HSPB1, CCT2); 14-3-3 
phosphoserine-binding proteins (YWHAZ, YWHAE, YWHAQ, YWHAH); cytoskeletal 
proteins (ACTB, CTTN,  TUBB4A, MTPN); membrane traffic-associated proteins (CLTC, 
NDRG1), and signaling adaptor proteins (GIPC1, LASP1, PEA15, CRK, CRKL, GRB2; 
Figures 6, S14). Clathrin heavy chain (CLTC) also decreased in endosome fractions 
(org2) in response to geldanamycin, while other proteins increased, including MAPK1, 
MAPK12, and KRAS (Figure 6C, D, E). While there was a geldanamycin-induced 
increase in phosphorylated MAPK3/MAPK1 in raft fractions, phosphorylated CTTN 
decreased in the same fractions (p-ERK1/2 and p-CTTN, Figure 6E, S14). 
Concomitantly, several bromodomain-containing proteins (PBRM1, ATAD2, BAZ1A, 
BAZ1B, and SMARCA4) decreased in the same lipid raft fractions (raft2-4; Figure 6B, 
C). These data are consistent with previous work showing that geldanamycin influences 
the intracellular localization of signaling proteins (43-45) and support the hypothesis that 
changes in modification state that we observed in response to geldanamycin (Figure 3) 
have functional consequences for intracellular localization.  
We also examined relationships between protein methylation and other PTMs. The 
distribution of correlations between methylation and acetylation sites on the same 
protein was significantly different than correlations of the same PTMs (Figure 7A). There 
were 50 proteins with 95 dual acetylation and methylation PTMs that had negative 
correlation less than –0.5 (highlighted in blue in Figure 7A). These include RNA binding, 
cytoskeletal, heat shock proteins, transcription factors, and acetyltransferases, including 
EP300 and NCOR2 (the complete list can be found in Supporting Table S1). Note that 
none of this group were histones, which were dually modified, but correlations were 
mostly positive or not significant. Figure 7B shows an example clique, identified by 
multiple yellow edges, of methylation and acetylation PTMs on several RNA binding 
proteins and transcription factors, including the methyltransferase EZH1, 
acetyltransferase CREBP, deacetylase SIRT9, and proteins whose methylation and 
acetylation sites were inversely correlated. These data suggest that there are molecular 
interactions governed antagonistically by methylation and acetylation in proteins to 
regulate RNA processing and transcription. 
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Similar to other dual modifications on the same proteins, the distribution of PTM 
correlations among 96 dually phosphorylated/methylated proteins were distinct from 
homologous PTM correlations, with 211 modifications having negative correlation 
between phosphorylation and methylation less than –0.5 (Figure 7C). Many of these 
were also RNA binding and RNA processing proteins. Figure 7D shows a clique of 
PTMs among phosphorylated and methylated RNA binding proteins and their links to 
methyltransferases and kinases. The core clique of proteins whose PTMs all cluster and 
correlate is involved in RNA splicing and processing, as is the clique in Figure 7B (48). 
The extended group contains other proteins involved in RNA binding, cytoskeleton, 
chaperone activity, and transcription regulation. HNRNPA2B1 displays multiple negative 
correlations between its tyrosine phosphorylation and arginine methylation sites. Note 
that the methyltransferase EZH1, the RNA processing protein XRN2, and the RNA 
binding protein RBMX are linked to both clusters in Figure 7. Table S1 lists other 
proteins with three different types of modifications that have negative correlations 
among different PTMs.   
Connections to aberrantly regulated genes in lung cancer
Lastly, to assess the functional significance of upstream signaling events’ influence on 
global mRNA gene expression by post-translational modifications, we examined how 
cell signaling pathways inferred from the CFN analysis may regulate basal gene 
expression patterns in lung cancer cell lines. Among the most commonly differentially 
regulated genes from the gene expression data we obtained from lung cancer cell lines 
from the Cancer Cell Line Encyclopedia (CCLE) (49), SMARCA4 and NKX2-1 were also 
detected in the protein modification data (Figure 8A; ref. (50)). SMARCA4 is the most 
down-regulated gene and its inactivation is thought to promote NSCLC aggressiveness 
(51). NKX2-1 is one of the top 10 differentially regulated gene in this set of cell lines. 
NKX2-1 plays a key role in lung development; its loss causes a failure of lung cell 
differentiation and leads to malignant transformation in lung adenocarcinoma (52-54).  
SMARCA4 and NKX2-1 exhibited CFN/CCCN interactions with the RNA binding 
proteins DDX5, DHX9, HNRNPAB, and lysine acetyltransferase NCOA2 (Figure 8B). 
These links from DDX5 to NCOA2, NKX2-1, and SMARCA4 were preserved in a highly 
curated network focused on direct binding interactions (Figure 8C). This is consistent 
with a mechanism to control NKX2-1 expression through long non-coding RNAs(54). 
The acetyltransferase EP300, the methyltransferase PRMT1, and the kinases PKN2, 
CHEK2, YES1, and the bromodomain-containing kinase BAZ1A also have cluster-
filtered interactions with this group (Figure 8B), indicating that the interplay of 
phosphorylation, acetylation, and methylation is likely to play a role in controlling 
expression and activity of SMARCA4 and NKX2-1.  
In sum, a large number of proteins are modified by more than one type of PTM; in this 
study we detected more than 700 proteins that are phosphorylated, acetylated, and 
methylated (Figures 9A, S15A). Correlation was poor (R-squared 0.03368) comparing 
relative abundance of proteins detected by their PTMs in our data to total protein 
abundance estimates for human proteins in paxDB (Figure S15B) (56).This suggests 
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that the amount of detectable PTMs is governed largely by signaling events rather than 
by total protein amounts. Elucidation clusters of positively correlated PTMs, when 
combined with PPI information, identifies cell signaling pathways that are active in lung 
cancer cell lines. In addition, our observations suggest that proteins that function as 
signal integrating hubs may have one or more exclusive OR (XOR) switches governed 
by a subset of antagonistic relationships among phosphorylation, acetylation, and 
methylation sites (Figure 9B). Since different PTMs govern interactions with proteins 
with PTM-specific binding domains (Figure 9B), proteins modified by more than one 
PTM type may thus function as hubs for signal integration or pathway control switches. 
Identification of these cell signaling hubs, and the enzymes that modify them, provides 
insight into the complex signal transduction mechanisms that regulate lung cancer cell 
lines.
Discussion
This study presents a unique opportunity to simultaneously examine, on a large scale, 
proteins modified by tyrosine and serine/threonine phosphorylation, lysine acetylation 
and lysine and arginine methylation (Figure 1B). This allows definition of relationships 
between kinases, phosphatases, and enzymes known to affect other post-translational 
modifications, including acetyltransferases, deacetylases, methyltransferases, and 
demethylases. Our computational data analysis approach was to integrate two different 
kinds of information: clustering based on statistical relationships among various PTMs, 
and PPI data from public databases, to outline signal transduction pathways (Figure 
1A). We started with PPI networks retrieved from Pathway Commons, String, 
GeneMANIA (15, 16), BioPlex (12), and the kinase-substrate data from 
PhosphositePlus (13, 14), and filtered interactions based on PTM clustering. Clustering 
methods using t-SNE were previously used for analyzing lung cancer 
phosphoproteomic data (23) and the CFN approach we employed here was previously 
used on phosphoproteomic data from neuroblastoma cell lines (10). We further refined 
this approach with an additional step (PMD) to break up large clusters as described in 
Materials and Methods and Supplementary Information. We have shown that the CFN 
derived from these data effectively removes biases in PPI networks where well-studied 
proteins have more links (Figure S6) and that the number of PTMs does not overly bias 
node betweenness (Figure S7), so that the two kinds of information are well balanced 
for construction of a CFN. 
The cell signaling pathways within the CFN will be based on known PPIs as well as 
clustering of PTMs in lung cancer cell lines, because for interactions between any two 
proteins to be retained in the CFN, they must be included in the same PTM cluster. 
Starting with drug targets (the proteins that bind to and are directly affected by drugs) 
we examined links, shortest paths in the CFN, to proteins whose PTMs were changed 
by drug treatment (Figures 2, 3). This effectively outlines signaling pathways in lung 
cancer cell lines between drug targets and downstream proteins whose PTMs were 
affected by the drug.  
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The hypothesis that certain PTMs may have a mutually opposing, antagonistic 
relationship to one another was first suggested in our results by drug treatments that 
caused protein acetylation to increase and phosphorylation to concomitantly decrease 
(Figures 2, 3). The links between the acetyltransferase EP300 and heat shock proteins 
including HSP90s, suggested that the HSP90 inhibitor, geldanamycin, affects the 
balance between the phosphorylation and acetylation of endocytic and cytoskeletal 
proteins. This in turn perturbs endocytosis and cytoskeletal dynamics, which influences 
membrane trafficking and activity of selected RTKs and other proteins involved in signal 
transduction (Figure 6). These results are consistent with previous work showing that 
geldanamycin affects membrane traffic and cytoskeletal dynamics to regulate activity 
and intracellular localization of many signaling proteins (43-45). EP300 has many links 
to enzymes that regulate other PTMs, including kinases, phosphatases, and 
methyltransferases; Figures 4, S11, S12). EP300 has been previously reported to 
function in cytosol to regulate autophagy (57, 58). Our data suggest that EP300 (and 
possibly other acetyltransferases) may play a role in regulating other membrane traffic 
and cytoskeletal mechanisms. Consistent with this notion, HDAC6 acetyltrasferase 
regulates the acetylation status of microtubules and modulates EGFR trafficking(59). 
That geldanamycin affects the balance of different PTMs sheds new light on the elusive 
mechanisms of action of this class of drug, which is important to understand because 
HSP90 inhibitors are an emerging therapy for lung cancer (60-62).
Further support for an antagonistic relationship between certain phosphorylation and 
acetylation sites was provided by examining negative correlations between PTMs within 
the same protein, and visualizing them as edges (Figure 5A, B). In addition, cluster-
filtered interactions exist between kinase signaling pathways and bromodomain-
containing proteins that bind to acetylated lysine moieties (Figure 5E). These 
interactions were most frequent among proteins with negative correlations between 
phosphorylation and acetylation sites on the same protein (Figure 5F). In fact, negative 
correlations within proteins also exist for acetylation vs. methylation sites (Figure 7A, B), 
and phosphorylation vs. methylation sites (Figure 7C, D). These data elucidate a family 
of different PTMs that potentially function as multiple XOR (exclusive OR) switches in 
signaling pathways (Figure 9B). 
Our data are consistent with the notion that different PTMs on the same protein 
integrate multiple signals to generate combinatorial outputs(63). These interconnected, 
functionally-associated mechanisms co-evolved across eukaryotes(2, 64), and are 
associated with oncogenesis(40). Our study indicates that acetylation and methylation, 
together with phosphorylation, increase the interactome of hubs in the signal 
transduction network by conditionally altering the sets of interacting proteins with 
particular protein domains (Figure 9; refs. 65, 66). Proteins in the network may be 
classified as proteins that attach (writers), recognize (readers), and remove (erasers) 
PTMs (2). The readers of acetylation contain bromo and BET domains (5). Readers of 
methylation are proteins that have the tudor domain for arginine methylation; and 
chromo, MBD, and PWWP domains for lysine methylation(67). It is noteworthy that 
bromo-domain-containing proteins include kinases (BAZ1A; TRIM33; BRD2; BRD4), 
acetyltransferases (EP300; CREBBP), and methyltransferases (ASH1L; KMT2A; Figure 
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5E). This emphasizes the interconnected nature of mechanisms involving different 
PTMs.
Signaling pathways outlined using cluster-filtered networks involve a large number of 
modified RNA binding, cytoskeletal, and membrane traffic proteins. The number of 
RNA-binding and cytoskeletal proteins in these networks makes sense in light of the 
number of mechanisms involved with RNA transport, sequestration, and regulatory RNA 
molecules (68-72). Cells evolved mechanisms to control protein expression by 
transcription, translation, and transport of RNA to different intracellular locations. Two 
RNA binding proteins were the most highly modified proteins in the data (AHNAK, 
SRRM2; Figure S7). Several such highly modified RNA binding proteins are 
dysregulated in cancer and move from cytoplasm to nucleus in response to 
phosphorylation (73). Our data suggest that methylation and acetylation also likely play 
a role in this process.
Signal transduction involves more than the three PTMs studied here, for example 
generation of second messengers, and covalent attachment of carbohydrates, lipids, or 
ubiquitin-family proteins, which cause additional changes in activity, intracellular 
location, and binding partners(63-65). Accurate models of signal transduction should 
attempt to integrate data about these processes for a complete picture. For example, 
MET ubiquitination and internalization is regulated by MET pY1003, the c-CBL E3 
ubiquitin ligase binding site (74). This PTM on MET clusters with EGFR pY869  and 
pY1197 but not EGFR pY1045, EGFR’s c-CBL binding site (Figure 5C,D)(75). 
It would also be useful to correlate gene expression patterns with PTMs. This remains 
challenging, however, because the correlation between protein and mRNA levels is 
poor, as shown for example during Xenopus embryogenesis, where large cells allow 
direct comparisons (76), though many differences may be resolved using simple model 
for expression kinetics (77). PTMs in cells are even more highly variable and dynamic 
than protein levels. For example, very different phosphorylation patterns in the 
anaphase promoting complex and mitotic spindle checkpoint proteins were observed in 
response to antimitotic drugs (78), and PTMs show much more dramatic changes than 
mRNA or protein during developmental progression (77). PTMs are more likely to be 
useful to inform us about cell signaling pathways than transcription because they are 
closer to signaling events, at least those that are upstream of transcription (25, 77).  
Our study integrating three different PTMs contains a large amount of information that 
outlines signaling pathways when clustering is combined with known protein-protein 
interactions. These data elucidate clusters of highly-correlated PTMs among groups of 
proteins (yellow CCCN edges in Figures 5B and 6B, D). This means that if one or a few 
of these PTMs are detected, other members of the clique are likely to be found, which is 
useful for determining signatures of pathway activation or disease state. This study not 
only brings home the message that there are dueling or antagonistic relationships 
among different PTMs, but illustrates specific cases in lung cancer signaling pathways 
where these relationships occur. We have created a browser-accessible interface as a 
resource for further exploration by other investigators (https://
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cynetworkbrowser.umt.edu). The data will be useful for prediction of pathways of drug 
resistance (79), and side effects from drugs that target writers, readers and erasers of 
acetylation and methylation (4-9). 
Materials and Methods
Modification-specific antibody immunoprecipitation and Mass spectrometry. 
PTMs of 45 lung cancer cell lines, 12 derived from SCLC and 33 from NSCLC, were 
compared to normal lung tissue (pooled from anonymous patients) using an established 
protocol (26, 27). In addition, several cell lines were treated with crizotinib, gefitinib, 
geldanamycin, or imatinib at 1 µM for 1-24 hours. In all, 15 six-plex TMT experiments 
were performed. Briefly, cells were washed and harvested in PBS and cell pellets frozen 
in liquid nitrogen. Cells were lysed in a 10:1 (vol/wt) volume of lysis buffer (4% SDS; 100 
mM NaCl; 20mM HEPES pH 8.5, 5 mM DTT, 2.5 mM sodium pyrophosphate; 1 mM β-
glycerophosphate; 1 mM Na3VO4; 1 μg/ml leupeptin), and proteins were reduced at 
60°C for 45 min. Proteins were then alkylated by the addition of 10 mM iodoactamide 
(Sigma) for 15 min at room temperature in the dark, and methanol/chloroform 
precipitated. Protein pellets were resuspended in urea lysis buffer (8M urea; 20 mM 
HEPES pH 8.0; 1 mM sodium orthovanadate; 2.5 mM sodium pyrophosphate; 1 mM 
beta-glycerolphosphate) and sonicated. Insoluble material was removed by 
centrifugation 10,000 x g, 5 min, and the supernatant diluted fourfold in 20 mM HEPES 
pH 8.5, 1 mM CaCl2, for Lys-C digestion overnight at 37°C, then diluted two-fold and 
trypsin digestion 4-6 hours at 37°C. Samples were then acidified to pH 2-3 with formic 
acid, peptides purified on a Waters Sep-Pak column and dried in a speed-vac. Peptides 
were purified on a Waters Sep-Pak column, and quantified using a micro-BCA assay 
(Thermo). Mass tag (6-plex TMT reagents; Thermo) were crosslinked to peptides in 
30% acetonitrile/200 mM HEPES pH 8.5 1 hr at room temperature and the reaction 
stopped by the addition of 0.3% (v/v) hydroxyamine. Combined samples were then 
sequentially immunoprecipitated with cocktails of modification-specific antibodies from 
Cell Signaling Technology in the order: anti-phosphotyrosine (Phospho-Tyrosine P-
Tyr-1000 #8954); anti-phosphoserine/threonine (AGC/PSD-family Kinase Substrate 
Antibody [CST in-house antibody validated for peptide immunoprecipitation], Phospho-
Akt Substrate #9614, Phospho-AMPK Substrate Motif #5759, Phospho-ATM/ATR 
Substrate #9607 and #6966); anti-acetyllysine (Acetylated-Lysine #9814(80));  anti-
methyllysine (Mono-Methyl Lysine #14679(81)) and anti-methylarginine (Mono-Methyl 
Arginine #8015(81))  (see Figure 1B). After anti-phosphotyrosine and anti-
phosphoserine/threonine immunoprecipitation phosphopeptides were further purified on 
a TiO2 column (Thermo Fisher(82)). Samples are then mixed in equimolar ratios, and 
the ratios checked and samples run on an Orbitrap Q Exactive MS (Thermo Fisher). 
Identification of peptides and quantification of mass tags was obtained from the from the 
MS2 spectrum after fragmentation by MS/MS analysis as described (28, 81). Peptides 
with FDR < 1% were selected for further analysis. Modification sites with site localization 
scores of less that A-score 13 were excluded from analysis(83).The data were filtered to 
include single modification sites present in three or more experiments for the final 
analysis. For display of results in heat maps, treatment:control ratios were calculated as 
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fold change (treatment/control if treatment>control; -1/treatment/control if 
treatment<control). 
Protein-proteins interaction edges were retrieved from Pathway Commons as 
described above, and from STRING, GeneMANIA (using the website or the Cytoscape 
plugin)(15, 16), BioPlex (12), and the kinase-substrate data from PhosphositePlus (13, 
14). Text-mining, colocalization, and co-expression edges were excluded to focus on 
interactions that are likely part of cell signaling pathways. We found it most useful to 
limit interactions to those defined by direct physical interactions from curated pathways. 
For example, genetic interactions may be direct or indirect, so they were excluded in 
some cases to focus on direct physical interactions (84). A CFN was constructed from a 
PPI dataset with highly curated molecular interactions with a focus on direct interactions 
for which there is strong evidence (Figure 8C; refs. 20, 55).
Final clustering for cluster-filtered networks. TMT ratio data was used to calculate 
pairwise-complete Euclidean distance, Spearman and hybrid Spearman-Euclidean 
dissimilarity (SED) (10, 23). Clusters were identified using t-SNE as described in detail 
in the Supplementary Information. Clusters containing more than 80 modifications were 
subjected to PMD with dimensionality reduced to the number of experiments that 
contained modifications in the cluster and t-SNE was then performed on these PMD 
embeddings. Clusters were examined manually and those that were sparsely populated 
with data (i.e., that contained modifications mostly from one experiment) were 
discarded. An adjacency matrix was constructed by pairing co-clustered modifications to 
each other. To construct co-cluster correlation networks (CCCNs), the adjacency matrix 
was used to filter Spearman correlations at various values as shown in Figure S9, 
excluding values not between co-clustered modifications. Spearman correlation values 
were used to represent network edge weights in modification site CCCNs. This protein 
modification CCCN was used to construct a protein CCCN by merging all co-clustered 
correlation edges into the gene names of modified proteins. The final gene CCCN 
represents the sum of modification correlations among all proteins (genes) that 
clustered together, whose modifications were detected in two or more experiments, and 
whose Spearman correlation is greater than the absolute value of minimum densities 
shown in Figure S9B.
Network analyses. For the CCCN we used clustering to filter correlations between all 
sites. The resulting protein CCCN was used to create a cluster-filtered network (CFN) of 
PPI interactions that were filtered based on clustering by excluding all interactions save 
those from proteins with co-clustered modifications. To identify pathways that are likely 
to be active in lung cancer cell lines, shortest paths were determined using the R 
package, igraph (igraph.org). A composite of all shortest paths was assembled for 
Figures 2A, 2B, and 3D. Centrality was identified by node degree and betweenness, 
calculated using igraph functions. Networks were also graphed to show protein 
modifications with correlation edges from the CCCN. In the CCCN graphs, correlation 
edges depict PTMs that co-cluster with edges representing Spearman correlations 
greater than the threshold of |0.543| as defined in Figure S9. Additionally, for Figures 
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5B, 7B, and 7D, negative correlations less than –0.5 are shown between different 
modifications within the same protein. 
Website construction. To enable exploration of the networks in detail by other 
investigators, we developed a website for interactive visualization (https://
cynetworkbrowser.umt.edu). Our novel infrastructure allows a web client (browser) to 
interface to a server-based instance of Cytoscape. Networks and their underpinning
data are stored on the server as R data files, and each web session corresponds to a 
instance of Cytoscape on the server. The web client presents a graph rendered by the 
Javascript library, cytoscape.js. Actions on the site initiate queries to the Python server 
which in turn employs the R-to-python interface (rpy2) to call the relevant R function. R 
communicates with the server-based instance of Cytoscape via the RCy3 library 
(bioconductor.org)(85). The cyREST interface (86) returns updated graph information to 
the client, in the form of JSON data, by connecting Cytoscape to a Python Flask-WSGI 
server.   
Cell fractionation. H3122 cells were treated with 1 nM geldanamycin for 15 hours or 
not treated, then mechanically permeabilized using a Balch homogenizer (10, 46, 47). 
Permeabilized cells were centrifuged at 1000 x g 10 min, and the organelles in the 
supernatant applied to velocity sedimentation gradients as described previously (10, 
46). Four fractions were collected from organelle gradients as shown in Figure 9A. 
Lysosomes are found in fraction 1; endosomes in fractions 2-3 (10, 46). The 1000 x g 
pellet (cell ghosts) were solubilized 1.5 hours on ice in 1% Triton X-100 and subjected to 
floatation equilibrium gradients as described, except the 10,000 x g centrifugation step 
was omitted (10, 47). Four fractions from floatation equilibrium gradients were collected: 
fraction 1 is from the bottom of the gradient, fraction 2 contains the lipid rafts as 
previously characterized, and fractions 3 and 4 contain additional floating membranes at 
the top of the gradient as shown in Figure 9A. Samples were prepared for TMT mass 
spectrometry as described above except without immunoprecipitation with modification-
specific antibodies, so total protein amounts were measured; ten mass tag labels were 
used (Thermo TMTplex); and samples were analyzed on an Orbitrap Fusion Lumos 
(ThermoFisher). The iBAQ method was used to normalize signals, where a protein’s 
total intensity is divided by the number of tryptic peptides between 6 and 30 amino acids 
in length (87). Western blots using antibodies from Cell Signaling Technology (except 
ERK1/2, Santa Cruz sc-93) were used to verify results from selected proteins in 
duplicate experiments with H3122 and H3255 cells (훽-actin #4970; phospho-CTTN 
Tyr421 #4569; CTTN #3503; phospho-ERK1/2 Thr202/Tyr204 #4370; CCT2 #3561; 
CLTC #4796; CRKL #3182; LASP1 #8636; YWHAZ #7413). Duplicate blots were used 
to probe phospho- and non-phospho-CTTN and ERK1/2. Western blot 
chemiluminescent signals were obtained on a Fuji LAS-3000 and quantified using 
ImageGauge software. The amount of each protein in each fraction as a percent in the 
whole cell was then calculated by dividing western blot or mass spectrometry signals by 
the total in all fractions (10, 47). Treatment/control ratios were then calculated to 
compare geldanamycin-treated to control samples.
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Figure 1. Data acquisition and analysis. (A) A cluster filtered network (CFN) is created by using a machine 
learning, pattern recognition algorithm (t-SNE) to identify which post-translational modifications (PTMs) cluster 
together, and filtering protein-protein interactions (PPIs; red edges) to retain only those between proteins whose 
PTMs co-clustered. (B) Outline of TMT mass spectrometry coupled with immunoprecipitation using modification-
specific antibodies. Phospho S/T peptide immunoprecipitation was accomplished in multiple steps with AGC/PSD-
family kinase substrate, AKT substrate, AMP kinase substrate, and ATM/ATR substrate antibodies (see Materials 
and Methods). Phosphopeptides were also further purified on a TiO2 column (82). (C) Co-cluster correlation 
network (CCCN) that includes threshold-filtered Spearman correlations among t-SNE-clustered PTMs (yellow 
edges are positive correlation; blue, negative). Also shown are negative correlations among different modification 
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Figure 2. Networks derived from composite shortest paths from drug targets to drug-affected proteins. 
Graphs showing the sum of shortest paths from each target to each protein whose PTMs were more than 2-fold 
affected by the MET and ALK inhibitor crizotinib (A), and the EGFR, ERBB2, ERBB3 inhibitor gefitinib (iressa) (B). 
Many yellow nodes represent increases in acetylation in these graphs. Several proteins exhibited phosphorylation 
decreases and acetylation increases in response to gefitinib (C). Fold change in response to indicated drugs is 
plotted on a blue-yellow scale (see scale bar). Also shown is a key defining node shape and border colors and 




























































































































































































































































































































































































































































































































































Figure 3. Heat maps and network showing PTMs affected more than 2-fold by geldanamycin. (A) HSPs; (B) 
Proteins involved in endocytosis. Scale bar indicates fold change on a blue-yellow scale. (C) Proteins involved 
with the cytoskeleton. Node size and color indicates the sum of PTM changes in response to geldanamycin. (D) 
Graph showing the sum of shortest paths from HSP90AA1 and HSP90AB1 to each protein whose PTMs were 











































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 4. EP300 interactions with PTM-modifying enzymes. (A) EP300 links in the CFN to kinases, 
phosphatases, acetyl- and methyltransferases, and actin-polymerization-governing GTPases RAC1 and CDC42. 
(B) EP300 interacts with clathrin heavy chain (CLTC) and enzymes that modify clathrin, which governs EGFR 
endocytosis. This graph also shows PTMs linked by black edges to the parent protein, and correlation edges 
(yellow, positive; blue, negative) between PTMs in the PTM CCCN, which depicts PTMs that co-cluster with 
edges representing Spearman correlation greater than the threshold of |0.543| as defined in Figure S9. Node size 
and color indicates ratios of lung cancer cell lines to normal lung tissue; see Figure S11 for responses to drugs. 
The combined CFN/CCCN graphs show the individual PTM response as well as the sum of all PTMs represented 








































































































































































































































































Figure 5. Dually acetylated 
and phosphorylated 
proteins: interactions with 
bromodomain proteins and 
kinases. (A) Correlation 
between different PTM sites on 
the same protein: different 
phosphorylation sites (p p); 
phosphorylation and 
acetylation (p ac); and different 
acetylation sites (ac ac). 
Homo-PTM correlations (p p; 
ac ac) are significantly different 
from heterologous (p ac) PTMs 
(both p < 2.2 x 10-16, Welch 
two-sample t-test). Individual 
PTM-PTM correlations are 
plotted in grey under boxplots 
(top). Correlation density 
between phosphorylation and 
acetylation sites on the same 
proteins is also shown 
(bottom). Figure S13 shows 
similar plots in which tyrosine 
and serine/threonine 
phosphorylation are compared 
to each other and each to 
acetylation individually. 
Negative correlations selected 
for display as edges are 
highlighted in blue. (B) 
Combined CFN and PTM 
CCCN for selected proteins 
modified by both 
phosphorylation and 
acetylation. In addition to 
correlation edges negative 
Spearman correlations less 
than -0.5 are shown as blue 
edges (plotted as in Figure 4B 
except edges connecting 
proteins to their PTMs are light 
grey). (C,D) Selected regions of (B) expanded for clarity. (E) CFN interactions between tyrosine kinases, 
geldanamycin-affected dually acetylated and phosphorylated endocytic and cytoskeletal proteins and 
bromodomain proteins (highlighted in red). Node size and color is in response to geldanamycin for (B-D). (F) 
Comparison of the number of interactions of bromodomain-containing proteins with: dually modified proteins both 
phosphorylated and acetylated (p ac); those with negative correlations less than -0.5 (p ac neg); all acetylated 
proteins (all ac); all proteins not acetylated (all except ac); all proteins except those both phosphorylated and 
acetylated (all except p ac); and proteins only modified by phosphorylation (p only) or methylation (me only). CFN 
interactions between bromodomain-containing proteins and these groups of proteins were retrieved and the 





































EP300 ack K1760 EP300












































































































































































bromodomain interactions per gene








EP300 ack K1760 EP300











































































































































































EP300 ack K1760 EP300



































































































































































K4603 AHNAK p S5782
D
E
Figure 6. Geldanamycin induces 
changes in lipid raft localization 
of dually phosphorylated/
acetylated proteins. (A) Outline 
of cell fractionation experiments 
that separate organelles including 
different populations of 
endosomes (org1-4, top) and 
detergent-sensitive and -resistant 
membranes including lipid rafts 
(raft1-4, bottom). Org1-3 contain 
lysosomes and endosomes with 
different sedimentation velocity, 
respectively; org4 contains 
soluble, cytoplasmic proteins; raft1 
contains detergent-sensitive 
proteins; raft2-4 are detergent-
resistant fractions of decreasing 
equilibrium density (10, 46, 47). 
(B-E) H3122 and H3255 cells 
treated with geldanamycin or not 
treated were fractionated and total 
protein amounts in each fraction 
were determined in separate 
experiments by mass spectrometry 
(B, C; H3122 cells) and western 
blotting (D, H3255 cells; E; cell 
type indicated). Mass 
spectrometry data (expressed as 
heat maps in B) and western blot 
data (C; Figure S14) were used to 
calculate the amount of each 
protein in each cell fraction as a 
proportion of the total in the whole 
cell, which is the sum of protein 
amounts in all cell fractions. The 
heat maps in C and E show 
treatment:control fold change for 
each fraction for mass 
spectrometry and western blot 
data, respectively. 168/218 dually 
phosphorylated and acetylated 
proteins with negative correlations between these PTMs were detected in this experiment. Many exhibited 
changes in the raft2 fraction (p = 0.05394, Welch Two Sample t-test). 45/108 proteins whose PTMs changed 
significantly in response to geldanamycin (Figure 3) were detected by mass spectrometry in this experiment; 
collectively their amounts increased in the raft2 fraction (p = 0.01457). Of the six bromodomain-containing 
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Figure 7. Clusters of proteins dually modified by different PTMs. (A, C) Correlations between different PTM 
sites on the same protein plotted as in Figure 5A. Homo-PTM correlations (me me; ac ac; p p) are significantly 
different from heterologous PTM correlations (me ac; p me; p < 2.2 x 10-16 in all cases). Selected proteins 
modified by (B) acetylation and methylation, and (D) phosphorylation and methylation are shown with CFN links 
to PTM modifying enzymes as in Figure 4B. These figures highlight two cliques of PTM CCCN edges that co-
clustered and had a high Spearman correlation. Negative correlations between different PTMs on the same 
protein are indicated by blue edges. Node size and color reflects total of all PTM ratios in the data set.
Figure 7






























































































































































































































































Figure 8. Pathways to SMARCA4 and NKX2-1. (A) Gene expression data from 29 NSCLC cell lines from the 
Cancer Cell Line Encyclopedia (CCLE; ref. 49) plotted on a blue-red scale (key; ref. 50). NKX2-1 and SMARCA4 
(highlighted) are among the most dysregulated genes in lung cancer. (B) CFN and CCCN path from EP300 to 
NKX2-1 and SMARCA4, where node size and color indicates total ratio data for all experiments where lung 
cancer cell lines were compared to normal lung tissue. (C) Shortest paths from EGFR and MET to transcription 
factors in a CFN derived from PPI dataset with highly curated molecular interactions with a focus on direct 
interactions for which there is strong evidence(20, 55). Note that DDX5 and NCOA2 bind to NKX2-1 and 
SMARCA4 as in (B). Node size is CFN betweenness and node color is normalized betweenness defined as CFN 





































































































































































































































































































Figure 9. Dual PTMs may function as dueling PTMs. (A) Venn diagram showing the overlap among proteins 
modified by more than one type of PTM. Figure S15A shows a similar Venn diagram in which tyrosine and serine/
threonine phosphorylation are separated. (B) Proteins in molecular signaling pathways modified by more than one 
PTM have different sets of interacting proteins(5, 6). PTM-driven interactions occur via recognition of specifically 
modified amino acid residues by protein domains listed under the PTM type in the figure. Our data suggest that 
where inverse correlations exist between different PTMs, these may function as exclusive “OR” (XOR) switches to 
direct alternative cellular outcomes. This principle applies to phosphorylation vs. acetylation; phosphorylation vs. 
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